Detalhe da pesquisa
1.
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
Haematologica
; 109(1): 200-208, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646672
2.
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients.
Eur J Haematol
; 112(3): 367-370, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882735
3.
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Br J Haematol
; 200(1): 45-53, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36205375
4.
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Eur J Haematol
; 111(1): 63-71, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964939
5.
BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
Br J Haematol
; 196(6): 1329-1333, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075635
6.
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
Eur J Nucl Med Mol Imaging
; 49(3): 953-962, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480603
7.
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Ann Hematol
; 101(4): 755-762, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083525
8.
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Br J Haematol
; 195(2): 186-193, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196388
9.
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Eur J Haematol
; 106(2): 184-195, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090552
10.
Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients.
Thromb J
; 19(1): 79, 2021 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34736472
11.
Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma.
Eur J Haematol
; 105(1): 30-34, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32124519
12.
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma.
J Hematol Oncol
; 17(1): 21, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649972
13.
Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma.
J Clin Med
; 12(3)2023 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36769556
14.
Lymphoproliferative disease detected by breast cancer screening.
J Med Screen
; 29(4): 255-259, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35818749
15.
Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?
Cancers (Basel)
; 14(3)2022 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35159016
16.
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.
Bone Marrow Transplant
; 56(5): 1031-1037, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33230187
17.
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Nat Med
; 27(3): 491-503, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619369
18.
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
Clin Lymphoma Myeloma Leuk
; 20(11): e850-e857, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32624446
19.
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy.
Expert Opin Pharmacother
; 24(12): 1331-1334, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294016
20.
The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.
Leuk Lymphoma
; 64(10): 1727-1729, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37384591